Matthew Lei
YOU?
Author Swipe
View article: A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell Lymphoma
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell Lymphoma Open
Synchronous systemic and de novo secondary central nervous system (CNS) large B-cell lymphoma (LBCL) is an aggressive clinical entity with a historically poor prognosis. Given the rarity of this presentation, prospective studies are limite…
View article: A prospective study of prophylactic dexamethasone with glofitamab in relapsed/refractory large B-cell lymphoma
A prospective study of prophylactic dexamethasone with glofitamab in relapsed/refractory large B-cell lymphoma Open
View article: Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia Open
Patients with multiple myeloma (MM) and Waldenström macroglobulinemia (WM) have increased risk of severe coronavirus disease 2019. Impaired humoral responses to the primary vaccination series against severe acute respiratory syndrome coron…
View article: 323 | A PROSPECTIVE ANALYSIS OF THE SAFETY AND EFFICACY OF PROPHYLACTIC DEXAMETHASONE FOR GLOFITAMAB ADMINISTRATION IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA
323 | A PROSPECTIVE ANALYSIS OF THE SAFETY AND EFFICACY OF PROPHYLACTIC DEXAMETHASONE FOR GLOFITAMAB ADMINISTRATION IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA Open
View article: 414 | CT‐BASED BODY COMPOSITION IN PATIENTS WITH FOLLICULAR LYMPHOMA COMPARED WITH THE GENERAL POPULATION, AND ASSOCIATION BETWEEN BODY COMPOSITION AND LYMPHOMA OUTCOMES
414 | CT‐BASED BODY COMPOSITION IN PATIENTS WITH FOLLICULAR LYMPHOMA COMPARED WITH THE GENERAL POPULATION, AND ASSOCIATION BETWEEN BODY COMPOSITION AND LYMPHOMA OUTCOMES Open
View article: 324 | RAPID RAMP‐UP DOSING OF BI‐SPECIFIC ANTIBODIES IN RELAPSED OR REFRACTORY LARGE B‐CELL LYMPHOMA
324 | RAPID RAMP‐UP DOSING OF BI‐SPECIFIC ANTIBODIES IN RELAPSED OR REFRACTORY LARGE B‐CELL LYMPHOMA Open
View article: Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury
Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury Open
Cast nephropathy is the most common cause of acute kidney injury (AKI) in patients with multiple myeloma (MM). A prompt reversal of renal injury is paramount for improving clinical outcomes. Daratumumab, an anti-CD38 monoclonal antibody, h…
View article: Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational study
Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational study Open
View article: Practice efficiency and total cost of care with bispecifics and CAR-T in relapsed/refractory diffuse large B-cell lymphoma: an institutional perspective
Practice efficiency and total cost of care with bispecifics and CAR-T in relapsed/refractory diffuse large B-cell lymphoma: an institutional perspective Open
Aim: Novel treatment options for relapsed/refractory diffuse large B-cell lymphoma include T-cell targeting therapies. Practice efficiency and cost are important for informed treatment decisions.Materials/methods: An institut…
View article: Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma Open
Venetoclax-obinutuzumab (Ven-O) is frequently administered off-label in relapsed/refractory (r/r) CLL/SLL where venetoclax-rituximab is the approved regimen. We conducted this retrospective, real-world study to evaluate Ven-O in r/r CLL/SL…
View article: Addition of an NK1 receptor antagonist to standard antiemetic prophylaxis in patients with B-cell lymphoma receiving EPOCH
Addition of an NK1 receptor antagonist to standard antiemetic prophylaxis in patients with B-cell lymphoma receiving EPOCH Open
Purpose Data on the optimal management of patients with hematologic malignancies and chemotherapy-induced nausea and vomiting (CINV) are lacking. We report our institutional experience in patients with B-cell lymphoma receiving multiday do…
View article: A Retrospective Analysis of Clinical Characteristics, Treatment, and Outcomes in Large B‐cell Lymphomas with Synchronous Systemic and Central Nervous System Involvement
A Retrospective Analysis of Clinical Characteristics, Treatment, and Outcomes in Large B‐cell Lymphomas with Synchronous Systemic and Central Nervous System Involvement Open
Introduction: Large B-cell lymphoma with synchronous systemic and central nervous system (CNS) involvement at diagnosis is a rare entity with a poor prognosis. Prior data come from small heterogenous retrospective studies, and there is no …
View article: Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia Open
View article: Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma Open
Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma is a rare large B-cell lymphoma subtype that is characterized by a plasmablastic phenotype and an ALK gene fusion. ALK-positive large B-cell lymphoma is resistant to the first…
View article: The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm
The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm Open
Background Coronary vasospasm is a known side effect of 5-FU (fluorouracil) therapy. Beyond switching to non-5FU-based chemotherapy, there are no established treatments for 5-FU associated coronary vasospam. Our objective was to assess the…
View article: Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study
Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study Open
Chronic lymphocytic leukemia (CLL), the most common leukemia worldwide, is associated with increased COVID-19 mortality. Previous studies suggest only a portion of vaccinated CLL patients develop severe acute respiratory syndrome coronavir…
View article: COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia Open
BACKGROUND: Multiple myeloma (MM) and Waldenström macroglobulinemia (WM) are associated with significant immunoparesis. Based on the ongoing COVID-19 pandemic, there is an urgent need to understand whether patients are able to mount a suff…
View article: OAB-045: COVID-19 vaccine responsiveness in patients with Multiple Myeloma and Waldenström Macroglobulinemia
OAB-045: COVID-19 vaccine responsiveness in patients with Multiple Myeloma and Waldenström Macroglobulinemia Open
View article: The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil–Associated Coronary Vasospasm
The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil–Associated Coronary Vasospasm Open
View article: 995P CTNNB1 mutations in Chinese HCC patients and immune microenvironment related analysis
995P CTNNB1 mutations in Chinese HCC patients and immune microenvironment related analysis Open